← Back to Screener
Rezolute, Inc. Common Stock (NV) (RZLT)
Price$3.54
Favorite Metrics
Price vs S&P 500 (26W)-62.82%
Price vs S&P 500 (4W)45.02%
Market Capitalization$343.55M
All Metrics
Book Value / Share (Quarterly)$1.34
P/TBV (Annual)3.69x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.80
Price vs S&P 500 (YTD)49.48%
EPS (TTM)$-0.92
10-Day Avg Trading Volume1.51M
EPS Excl Extra (TTM)$-0.92
EPS (Annual)$-0.98
ROI (Annual)-45.90%
Cash / Share (Quarterly)$1.39
ROA (Last FY)-42.40%
EBITD / Share (TTM)$-0.97
ROE (5Y Avg)-50.92%
Cash Flow / Share (Annual)$-0.79
P/B Ratio2.68x
P/B Ratio (Quarterly)1.71x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-5.32x
ROA (TTM)-59.37%
EPS Incl Extra (Annual)$-0.98
Current Ratio (Annual)14.37x
Quick Ratio (Quarterly)13.95x
3-Month Avg Trading Volume5.85M
52-Week Price Return39.69%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.25
52-Week High$11.46
EPS Excl Extra (Annual)$-0.98
Tangible BV CAGR (5Y)2.95%
26-Week Price Return-58.83%
Quick Ratio (Annual)14.09x
13-Week Price Return43.03%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.18x
Enterprise Value$331.611
Book Value / Share Growth (5Y)8.24%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.93
3-Month Return Std Dev92.04%
Net Income / Employee (TTM)$-1
ROE (Last FY)-45.90%
Net Interest Coverage (Annual)-19.31x
EPS Basic Excl Extra (Annual)$-0.98
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.92
ROI (TTM)-64.81%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.25
Price vs S&P 500 (52W)9.86%
Year-to-Date Return52.12%
5-Day Price Return-1.64%
EPS Normalized (Annual)$-0.98
ROA (5Y Avg)-42.37%
Month-to-Date Return17.70%
Cash Flow / Share (TTM)$-1.10
EBITD / Share (Annual)$-1.05
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-45.33%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.92
P/TBV (Quarterly)3.69x
P/B Ratio (Annual)2.39x
Book Value / Share (Annual)$1.86
Price vs S&P 500 (13W)42.34%
Beta0.74x
Revenue / Share (TTM)$0.00
ROE (TTM)-64.81%
52-Week Low$1.07
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RZLTRezolute, Inc. Common Stock (NV) | — | — | — | — | $3.54 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Rezolute is a clinical-stage biopharmaceutical company developing therapies for rare metabolic diseases, including congenital hyperinsulinism, a rare endocrine disorder characterized by excessive insulin production and hypoglycemia. Its pipeline candidates aim to improve patient outcomes with reduced treatment burdens. Value creation depends on successful clinical development and regulatory approval.